HIGHLIGHTS
- who: Elisa Agostinetto from the (UNIVERSITY) have published the research: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer, in the Journal: (JOURNAL)
- what: This study demonstrated that the inclusion of the HER2 status allowed the model to perform better than the previous PREDICT version and Adjuvant! The authors aimed to investigate the prognostic performance of PREDICT in patients with HER2-positive early breast cancer who received trastuzumab-based therapy started concurrently with chemotherapy within the ALTTO trial. The study has some limitations that should be acknowledged. The study has several strengths . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.